Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 51655-967

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 51655-967). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51655-967-52 (51655 967 52 Rev A 06 23)

NDC: 51655-967-52 is the National Drug Code for Alfuzosin Hydrochloride Extended-Release Tablets, USP. Each tablet contains 10mg of Alfuzosin hydrochloride. This medication is available in a pack of 30 tablets and requires a prescription. It should be stored between 20°C - 25°C (68°F - 77°F), protected from light and moisture, and kept out of the reach of children. The repackaging has been done by Northwind Pharmaceuticals in Indianapolis, IN. The lot number provided is 0000000000, and the expiration date is 00/00/0000.*

FDA Label Image

Molecular Structure (Ef35abcf E0b6 4551 84cf A689ad11e6cd 01)

FDA Label Image

Figure 1 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 02)

FDA Label Image

Figure 2 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 03)

This text provides information regarding the mean change in a study comparing a placebo group (N=167) to a group taking altuzosin hydrochloride extended-release tablets (N=170). The study measured the mean change over a treatment period of 28, 56, and 84 days. The significance level (p-value) for the observed differences is indicated to be less than 0.001, suggesting a statistically significant effect of the treatment.*

FDA Label Image

Figure 3 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 04)

The text provided indicates a comparison of mean change between a placebo group (consisting of 152 individuals) and a group administered with alfuzosin hydrochloride extended-release tablets (consisting of 137 individuals) over a treatment period of 28, 56, and 84 days. The significance level of the test is indicated by **p < 0.01.*

FDA Label Image

Figure 4 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 05)

FDA Label Image

Figure 5 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 06)

FDA Label Image

Figure 6 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 07)

FDA Label Image

Figure 7 (Ef35abcf E0b6 4551 84cf A689ad11e6cd 08)

This text appears to be a table displaying the mean change in mL/s over different days of treatment for a Placebo group and a group receiving Altuzosin hydrochloride extended-release tablets. The table includes data for 14, 28, 56, and 84 days of treatment. The statistical significance (p-value) is also mentioned.*

FDA Label Image

Company Logo (Ef35abcf E0b6 4551 84cf A689ad11e6cd 09)

Not available*

FDA Label Image

Company Logo (Ef35abcf E0b6 4551 84cf A689ad11e6cd 10)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.